Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry's Drug Pricing Power Is Running On Fumes

Executive Summary

Pharma is facing a big headwind in 2019 in the form of diminished drug pricing power. The pricing trend puts net drug prices squarely in the red for most large pharma manufacturers, but US lawmakers aren't likely to be reassured heading into an upcoming hearing on drug pricing.

Advertisement

Related Content

Missed Opportunities: 10 Questions We Wish Senators Had Asked At The Drug Pricing Hearing
The Rebate Effect: ‘Traditional’ Brand Costs Decline 6.5% In Commercial Plans
Pharma In The Crosshairs: Dual Drug Pricing Hearings Portend Rocky Road Ahead – And Potential Subpoenas
No More Rebates: HHS Proposed Rule Revises Anti-Kickback Safe Harbor
Pfizer: Time To Face The Lyrica Pain
Global Pharma Growth Poised To Moderate, IQVIA Predicts
J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124634

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel